Shorts

0:49

Why are Experts Hopeful About the 2026 ASCO Annual Meeting?

3 months ago

Nicholas James Hornstein, MD, PhD

Nathan Goodyear, MD, discussed exercise as an interventional biologic therapy to supplement standard-of-care anticancer therapies.

1:17

Could Exercise Prime the Immune System for Systemic Anticancer Therapies?

3 months ago

Nathan Goodyear, MD

1:01

Daraxonrasib in 2L PDAC May be the GI Abstract of ASCO 2026

3 months ago

Nicholas James Hornstein, MD, PhD

Mary Steinbach, NP, APRN, highlighted the advantages of subcutaneous isatuximab-irfc delivered via an on-body injector (OBI), which conferred better patient-reported outcomes than the intravenous solution.

0:51

On-Body Injector Brings “Modern” Isatuximab Delivery for Multiple Myeloma

3 months ago

Mary Steinbach, NP, APRN

0:56

Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations

3 months ago

Dana Chase, MD

Following the FDA approval of ruxolitinib extended-release tablets (Jakafi XR) across different myelofibrosis, polycythemia vera, and graft-versus-host disease populations, Naveen Pemmaraju, MD, spoke with CancerNetwork® about what this regulatory decision may mean for hematologic oncology practice.

0:31

How Might Extended-Release Ruxolitinib Tablets Impact Delivery of Care?

3 months ago

Naveen Pemmaraju, MD

Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO, discussed the impact of the Waterless Empirical Taste Test on better identifying and proactively managing oral adverse effects, including dysgeusia, that emerge with talquetamab among patients with multiple myeloma.

0:47

Examining the Impact of the WETT Tool on Talquetamab-Related Oral AEs

3 months ago

Beth Faiman, PhD, MSN, APN-BC

0:55

Prior Interstitial Lung Disease and Ocular Toxicity Pose ADC Treatment Risks

4 months ago

Dana Chase, MD

1:22

Keep 3, Cut 3: Essential Oncology Journals

4 months ago

Balazs Halmos, MD, MS

1:25

The Four Types of Therapy for Second-Line Endometrial Cancer

4 months ago

Dana Chase, MD

1:15

The Ultimate Oncology Conference Bracket

4 months ago

Balazs Halmos, MD, MS

0:43

Expanding the Use of TILs in Metastatic Melanoma Care

4 months ago

Hua-Jay Cherng, MD, discussed how markers such as ctDNA and MRD can translate to actionable strategies for lymphomas.

0:58

Is There Potential for a More Minimally Invasive Alternative to Biopsy?

4 months ago

Hua-Jay J Cherng, MD

Hua-Jay Cherng, MD, discussed how clinicians may be able to get the most out of assessment tools that could be used to inform treatment decision-making processes among lymphoma groups.

1:24

Optimizing the Use of Assessment Tools in Lymphoma Care

4 months ago

Hua-Jay J Cherng, MD

1:00

A Potential Breakthrough With TILs in Metastatic Melanoma

4 months ago

Muhammad Umair Mushtaq, MD

2:15

Blind Ranking Practice-Changing Lung Cancer Trials

4 months ago

Balazs Halmos, MD, MS

Jennifer Effie Amengual, MD, explained how “ancient” endogenous retroviruses can be reactivated by epigenetic therapies to serve as novel targets for immunotherapy in lymphoma.

0:48

Leveraging Ancient Viral Genes to Fight Lymphoma

4 months ago

Jennifer Effie Amengual, MD

Most patients with resectable pancreatic or peripancreatic cancer are candidates for the robotic Whipple surgery, according to Mohamed Adam, MD.

1:12

Who Should Be Selected for Robotic vs Open Pancreaticoduodenectomy?

4 months ago

Mohamed Adam, MD

Hiba Siddiqui, BSc, discussed the mechanism by which engineered macrophage-based immunotherapies would target CD44-expressing bladder cancers.

0:38

Detecting Specific CD44 Types in Bladder Cancer With CAR Macrophage Therapy

4 months ago

Hiba Siddiqui, BSc

1:39

The Mount Rushmore of Oncology

4 months ago

Balazs Halmos, MD, MS

In a conversation with CancerNetwork®, Jonathan Wesley Riess, MD, MS, spoke about efficacy findings from the phase 1/1b RMC-9805-001 study (NCT06040541) that he and colleagues presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

0:52

How Effective Is Zoldonrasib in KRAS G12D+ Non–Small Cell Lung Cancer?

4 months ago

Jonathan Riess, MD, MS

0:57

Life After The Whipple Surgery: Grocery Shopping 7 Days Later

4 months ago

Mohamed Adam, MD

0:56

The Excitement Brewing Around Plixorafenib in BRAF-Altered Cancers

4 months ago

Macarena de la Fuente, MD

After the 2026 National ICE-T Conference in Charlotte, North Carolina, Barry Paul, MD, spoke with CancerNetwork® about key points of discussion in the multiple myeloma paradigm, which included the potential role of fixed-duration therapy with bispecific antibodies.

0:46

Finding a “Sweet Spot” for Fixed-Duration Multiple Myeloma Therapy

4 months ago

Barry Paul, MD

Prerna Mewawalla, MD, spoke with CancerNetwork® about key takeaways from a presentation she gave at the 2026 National ICE-T Conference in Charlotte, North Carolina, which focused on the multiple myeloma therapeutic landscape.

0:33

Therapy is Only as Good as Its Access in Multiple Myeloma Care

4 months ago

Prerna Mewawalla, MD

0:49

How Emotional Intelligence Can Reduce Physician Burnout

4 months ago

MinhTri Nguyen, MD

Craig H. Moskowitz, MD, highlighted a trend where treatment is initiated following initial diagnosis and staging in lymphoma, which he believes may be unnecessary.

0:48

Waiting for Molecular Marker Test Results to Optimize Lymphoma Care

4 months ago

Craig H. Moskowitz, MD

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, CancerNetwork® spoke with conference director Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, about the key takeaways of a session that focused on the expanding roles of bispecific antibodies and T-cell engagers in multiple myeloma, lymphoma, and leukemia.

0:49

Bridging Gaps of Care Via Bispecific Antibodies in Hematologic Oncology

4 months ago

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

1:02

Addressing Bottlenecks to Cancer Care in Rural Settings

4 months ago

MinhTri Nguyen, MD

Using genomic profiling to identify specific fusion partners to p16 among patients with translocation renal cell carcinoma has been challenging, according to Shikha Gupta, PhD.

0:58

Larger Studies Needed to Elucidate Fusion Partner to p16 in tRRC

4 months ago

Shikha Gupta, PhD

Shorts

Trending on CancerNetwork

Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA